SparingVision Alternatives & Competitors
12 companies similar to SparingVision — Genomic Medicines For Ocular Diseases
Companies similar to SparingVision
GenSight Biologics
Applying pathbreaking science to transform the lives of patients with severe retinal neuro...
Paris, France
AAVantgarde
Pioneering treatments for Stargardt disease and Usher 1B, addressing the root cause of the...
Homology Medicines
Dedicated to addressing the root cause of rare genetic diseases and promising hope for pat...
Rival Readout
Competing with SparingVision? We do this properly.
10 rivals, 90 days of dated moves, ranked by what matters and sourced, in 7 business days.
Reborna Biosciences, Inc.
Save the life of rare disease patients and the parents by RNA binding molecules.
Fujisawa, Japan
Evommune
Developing innovative therapies that target key drivers of chronic inflammatory diseases.
Palo Alto, United States
Lexeo Therapeutics
Advancing science with curative potential for both cardiovascular and APOE4 associated Alz...
New York, United States
Genespire
Biotechnology company focused on developing transformative gene therapies for patients aff...
Milan, Italy
Apollo Therapeutics
A transformative idea for transformative medicines
Portugal
Prime Medicine, Inc.
Delivering on the promise of Prime Editing
Cambridge, United States
Panacela Labs
Fostering biomedical breakthroughs for oncology and rare diseases through global collabora...
About SparingVision
SparingVision is a biotechnology startup dedicated to developing genomic medicines for ocular diseases. Founded in 2016, the company aims to revolutionize the treatment of ocular diseases by translating over 20 years of world-leading ophthalmic research into vision-saving therapies. The core focus of SparingVision's wo...
Development and delivery of innovative genomic medicines for ocular diseases
Patients affected by inherited retinal diseases and ocular disorders
Genomic Medicines, Ocular Diseases, Inherited Retinal Diseases, Gene-independent Treatments, Research And Development, Retinitis Pigmentosa, Vision-Saving Treatments, Investment, Therapeutic Innovation, Pipeline Development, Rare Disease Treatment, International Collaboration, Sight-saving Treatments, Venture Capital
Frequently Asked Questions
From the desk
Mapping a market? Start with a Rival Readout.
In 7 business days we read 10 rivals around SparingVision: 90 days of dated moves, ranked by what matters to you, each with its source. Fully credited if you continue.
Compiled from the BounceWatch company index. We last looked at SparingVision on 7 Jun 2025. The 12 companies listed here were last checked between 11 Sep 2024 and 30 Jun 2026. Where a field is blank here, it means we have not recorded it — not that the answer is zero. How we source and date this.
